The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis |
| |
Authors: | Vidya Limaye Colin Luke Graeme Tucker Catherine Hill Susan Lester Peter Blumbergs Peter Roberts-Thomson |
| |
Affiliation: | 1. Department of Rheumatology, Royal Adelaide Hospital, North Terrace, Adelaide, SA, 5000, Australia 2. Department of Medicine, University of Adelaide, Adelaide, SA, Australia 3. Epidemiology Branch, South Australian Department of Health, Adelaide, SA, Australia 4. Epidemiology Branch Health System Information and Performance Operations Division, SA Health, Adelaide, SA, Australia 5. Department of Rheumatology, The Queen Elizabeth Hospital, Adelaide, SA, Australia 6. Neuropathology Department, Hanson Institute, Institute of Medical and Veterinary Science, Frome Rd, Adelaide, SA, Australia 7. SA Pathology, Department of Health, Adelaide, SA, Australia
|
| |
Abstract: | The South Australian (SA) myositis database has registered all patients with biopsy-proven inflammatory myositis in SA from 1980 to 2009. We determined the incidence and associations of malignancy in myositis by linking this database with the SA cancer registry. Standardized incidence ratios (SIR) for malignancy were determined using the total SA population over the same time period, stratified by age and gender. The SIR for cancer in the myositis population (n = 373) was 1.39, p = 0.047. There was a trend towards an increased SIR in dermatomyositis but no increased risk of malignancy in polymyositis or inclusion body myositis. Malignancies of the lung and prostate were the commonest and 28 % of malignancies occurred within one year of IIM diagnosis. The odds of developing cancer were significantly raised in the presence of a shawl sign, male gender, and in patients with overlap syndrome or rheumatoid arthritis whilst myalgia was a significant protective factor. HLA-A28 allele was overrepresented in patients with malignancy (11 vs 2 %, p = 0.006). Patients in SA with myositis are at modestly increased risk for malignancy. We report clinical and genetic risk factors allowing the identification of patients at greatest risk for malignancy. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|